Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
K Asami, T Okuma, T Hirashima, M Kawahara, S Atagi… - Lung Cancer, 2013 - Elsevier
BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
A Inoue, K Kobayashi, K Usui, M Maemondo… - Journal of Clinical …, 2009 - ascopubs.org
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non–small-cell lung cancer with epidermal growth factor receptor gene …
A Inoue, T Suzuki, T Fukuhara, M Maemondo… - Journal of Clinical …, 2006 - ascopubs.org
Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of …
Purpose Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …
First-or second-line therapy with gefitinib produces equal survival in non–small cell lung cancer
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American journal of …, 2008 - atsjournals.org
Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
SW Lim, S Park, Y Kim, JH Cho, SE Park, H Lee… - Lung Cancer, 2018 - Elsevier
Objectives Several studies have demonstrated the promise of continuation of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) beyond progression in patients …
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) beyond progression in patients …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - Elsevier
BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …